August 2012
-
The British Pharmacopoeial Commission is requesting comment from OINDP manufacturers regarding proposed changes to its inhaled product monographs. The BP has posted a draft document authored by its Inhaled Products Working Party and has asked… Read more . . .
-
Mark Shepherd, Respiratory Physics Lab and Workshop Manager at Team Consulting, will attempt to set a world record by climbing to the top of the Empire State Building in New York City while carrying 125… Read more . . .
-
The University of Western Ontario has named particle technology researcher Jesse Zhu a 2012 Distinguished University Professorship winner. Zhu, a professor and Canada Research Chair in Powder Technology Applications in the Department of Chemical and… Read more . . .
-
Three Phase 3 studies of Novartis’s QVA149 indacaterol /glycopyrronium bromide dry powder inhaler for the treatment of COPD have met their primary endpoints according to the company. The SHINE study demonstrated superiority in trough FEV1… Read more . . .
-
Almirall has licensed European rights to aclidinium bromide, both as a monotherapy and in combination with formoterol to Italian pharmaceutical company Menarini. The agreement covers most of the EU except for the UK, the Netherlands… Read more . . .
-
After spurning repeated offers from Valeant, ISTA Pharmaceuticals has agreed to be acquired by Bausch + Lomb for $9.10 per share in cash, a total of about $500 million. Valeant had offered $7.50 per share.… Read more . . .
-
The FDA has issued a complete response letter to MAP Pharmaceuticals’ NDA for Levadex dihydroergotamine inhalation aerosol for the treatment of migraine headaches. According to MAP, “the FDA requested that the Company address issues relating… Read more . . .
-
A Massachusetts engineering firm called Enginasion has disclosed details of proprietary DPI-filling technology it says that it developed for a pharmaceutical client that needed accurate dispensing of a highly cohesive inhaled dry powder formulation into… Read more . . .
-
According to Teva, the FDA has approved its QNASL HFA beclomethasone dipropionate nasal aerosol for the treatment of seasonal and perennial allergic rhinitis in adults and children 12 years of age and older, and the… Read more . . .
-
Almirall has published full results from the ATTAIN (Aclidinium To Treat Airway obstruction In COPD patieNts) study in The European Respiratory Journal (ERJ). ATTAIN was a six-month double-blind placebo-controlled study that compared two doses of… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland